2 Monster Stocks in the Making

Viking Therapeutics (VKTX) and Axsome Therapeutics (AXSM) are identified as biotech companies with substantial growth prospects. Viking, a clinical-stage firm, is advancing promising weight-loss candidates, including VK2735 in Phase 3 trials, and a MASH treatment, targeting a rapidly expanding market despite inherent clinical risks. Axsome, already generating strong revenue with Q3 sales up 63% year-over-year to $171 million, is positioned for further expansion as its depression drug Auvelity aims for blockbuster status and potential label expansion into Alzheimer's agitation, complemented by a robust late-stage pipeline.

Analysis

Viking Therapeutics (VKTX) is strategically positioned in the rapidly expanding weight-loss market, projected to reach $150 billion by 2035. Its lead candidate, VK2735, a dual GLP-1/GIP agonist, is in Phase 3 for subcutaneous use and completed mid-stage trials for an oral formulation, showing promising efficacy. This dual formulation approach could enhance market accessibility and affordability.

Viking's pipeline also includes a preclinical weight-loss candidate and VK2809 for MASH, which passed Phase 2 studies. While significant upside exists from successful program approvals, its clinical-stage status presents inherent clinical and regulatory risks, positioning it as a high-risk investment.

Axsome Therapeutics (AXSM) demonstrates robust financial momentum, reporting Q3 revenue of $171 million, a 63% year-over-year increase, driven by its depression medicine, Auvelity. Launched in 2022, Auvelity is anticipated to achieve blockbuster status in depression alone, offering substantial sales growth runway.

Further growth for Axsome is expected from Auvelity's potential label expansion into Alzheimer's disease agitation, a market estimated to yield $1.5 billion to $3 billion in peak sales. The company's deep late-stage pipeline, including approved migraine treatment Symbravo, provides multiple catalysts for sustained revenue expansion.

Key Decisions for Investors

• Investors with an above-average risk appetite should consider Viking Therapeutics (VKTX) for exposure to the high-growth weight-loss market, contingent on successful clinical and regulatory milestones.
• Evaluate Axsome Therapeutics (AXSM) for its proven revenue growth, strong commercial product Auvelity, and deep late-stage pipeline offering multiple near-term catalysts and potential label expansions.
• Closely monitor clinical trial readouts, regulatory approvals, and market penetration rates for key products from both companies to assess their long-term growth trajectories.